Abstract
Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.
Original language | English |
---|---|
Article number | 459 |
Journal | Pharmaceutics |
Volume | 15 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2023 |
Externally published | Yes |
Keywords
- atherosclerotic cardiovascular disease
- cardiovascular prevention
- hyperlipidemia
- hypertriglyceridemia
- lipoprotein (a)